Scott Rodig
Overview
Explore the profile of Scott Rodig including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
76
Citations
7905
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Ricciuti B, Elkrief A, Alessi J, Wang X, Li Y, Gupta H, et al.
Clin Cancer Res
. 2023 Apr;
29(13):2540-2550.
PMID: 37097610
Purpose: ATM is the most commonly mutated DNA damage and repair gene in non-small cell lung cancer (NSCLC); however, limited characterization has been pursued. Experimental Design: Clinicopathologic, genomic, and treatment...
12.
Gadi D, Martindale S, Chiu P, Khalsa J, Chen P, Fernandes S, et al.
Blood Cancer J
. 2023 Feb;
13(1):22.
PMID: 36732326
PI3Kδ inhibitors are approved for the therapy of B cell malignancies, but their clinical use has been limited by unpredictable autoimmune toxicity, despite promising efficacy and evidence that toxicity is...
13.
Nyman J, Denize T, Bakouny Z, Labaki C, Titchen B, Bi K, et al.
bioRxiv
. 2023 Jan;
PMID: 36712053
Clear cell renal cell carcinoma (ccRCC) is molecularly heterogeneous, immune infiltrated, and selectively sensitive to immune checkpoint inhibition (ICI). Established histopathology paradigms like nuclear grade have baseline prognostic relevance for...
14.
Le Y, Gao H, Zhu A, Felt K, Rodig S, Bleday R, et al.
iScience
. 2022 Nov;
25(11):105426.
PMID: 36388981
Limited therapeutic efficacy and severe side effects represent the central hurdles facing cancer chemotherapy. Immune suppression within tumor immune microenvironments (TIME) has been implicated in chemoresistance. In this study, using...
15.
Barroso-Sousa R, Forman J, Collier K, Weber Z, Jammihal T, Kao K, et al.
JCO Precis Oncol
. 2022 Jul;
6:e2100413.
PMID: 35797509
Purpose: In metastatic triple-negative breast cancer (mTNBC), consistent biomarkers of immune checkpoint inhibitor (ICI) therapy benefit remain elusive. We evaluated the immune, genomic, and transcriptomic landscape of mTNBC in patients...
16.
Yao S, Campbell P, Ugai T, Gierach G, Abubakar M, Adalsteinsson V, et al.
Cancer Causes Control
. 2022 Jun;
33(8):1107-1120.
PMID: 35759080
Cancer heterogeneities hold the key to a deeper understanding of cancer etiology and progression and the discovery of more precise cancer therapy. Modern pathological and molecular technologies offer a powerful...
17.
Rahma O, Tyan K, Giobbie-Hurder A, Brohl A, Bedard P, Renouf D, et al.
J Immunother Cancer
. 2022 Mar;
10(3).
PMID: 35264434
Background: The combination of antiangiogenic agents with immune checkpoint inhibitors could potentially overcome immune suppression driven by tumor angiogenesis. We report results from a phase IB study of ziv-aflibercept plus...
18.
Shah H, Wang Y, Cheng S, Gunasti L, Chen Y, Lako A, et al.
JAMA Otolaryngol Head Neck Surg
. 2022 Jan;
148(3):268-276.
PMID: 35050348
Importance: Neoadjuvant immunotherapy is a novel approach with the potential to improve outcomes for patients with oral cavity squamous cell cancer (OCSCC). Adverse events of varying severity are reported with...
19.
Akturk G, Parra E, Gjini E, Lako A, Lee J, Neuberg D, et al.
Clin Cancer Res
. 2021 Jul;
27(18):5072-5083.
PMID: 34253580
Purpose: The Cancer Immune Monitoring and Analysis Centers - Cancer Immunologic Data Commons (CIMAC-CIDC) network supported by the NCI Cancer Moonshot initiative was established to provide correlative analyses for clinical...
20.
Mehta A, Cheney E, Hartl C, Pantelidou C, Oliwa M, Castrillon J, et al.
Nat Cancer
. 2021 Mar;
2(1):66-82.
PMID: 33738458
Despite objective responses to PARP inhibition and improvements in progression-free survival compared to standard chemotherapy in patients with BRCA-associated triple-negative breast cancer (TNBC), benefits are transitory. Using high dimensional single-cell...